About GenePath Diagnostics
GenePath Diagnostics is a Healthcare company based in Pune (India) founded in 2008 by Nickhil Jakatdar and Nikhil Phadke. Provider of diagnostic solutions for infectious diseases, cancers and genetic disorders. GenePath Diagnostics has raised $1.85 million across 6 funding rounds from investors including Saama Capital, Snow Leopard Global and Snow Leopard Ventures. GenePath Diagnostics was last valued at $3.49 million in February 2016. Its chief executive, as recorded, is Nickhil Jakatdar. Its Indian entity Genepath Diagnostics India Private Limited reported revenue of ₹6.93 Cr. GenePath Diagnostics offers products and services including Custom Reagents, STI Kits, UTI Assays, and Respiratory Tests. Its focus areas include Diversified Diagnostics, Tests, Life Sciences and Genomics.
Company details
GenePath Diagnostics was founded in 2008 in Pune, India, as a provider of diagnostic solutions targeting infectious diseases, cancers, and genetic disorders. DNA and RNA-based tests are included in the portfolio, covering oncology, endocrinology, transplantation typing, hematology, pharmacogenetics, and pre-natal genetic testing. Detection services for HPV and COVID-19 infections are also handled, with operations focused on the biotechnology and healthcare sectors.
- Headquarters Pune, India
- Founders Nickhil Jakatdar, Nikhil Phadke
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website genepathdx.com
- Social LinkedIn X Facebook
- Legal Name Genepath Diagnostics India Private Limited
- Date of Incorporation 29 Jan, 2019
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹6.93 Cr
FY 2025 · -25% YoY
- Net Loss-₹4.91 Cr
FY 2025 · -71% margin
- EBITDA-₹3.05 Cr
FY 2025 · -44% margin
- Total Equity Funding$1.85M (USD)
in 6 rounds
- Latest Funding Round$336.88K (USD), Grant
Nov 2020
- InvestorsSaama Capital
& 9 more
Associated legal entities of GenePath Diagnostics
GenePath Diagnostics is associated with 2 registered companies on The Company Check; the primary company is Genepath Diagnostics India Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Genepath Diagnostics India Private Limited CIN U74999PN2019PTC181759 | Active | 29 Jan 2019 | Pune, Maharashtra | ₹6.9 Cr | 52 | 2 | View details |
| Causeway Healthcare Private Limited CIN U73100PN2008PTC131542 | Active | 04 Mar 2008 | Pune, Maharashtra | ₹0.0 Cr | 18 | 2 | View details |
Products & Services of GenePath Diagnostics
GenePath Diagnostics offers a comprehensive portfolio of products and services, including Custom Reagents, STI Kits, UTI Assays, and Respiratory Tests.
Reagents for molecular testing in infectious diseases
Kits for sexually transmitted infection testing
Assays for urinary tract infection detection
Tests for respiratory and vector-borne diseases
Funding Insights of GenePath Diagnostics
GenePath Diagnostics has successfully raised a total of $1.85M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $336.88 thousand completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.85M
- Total Rounds 6
- Last Round Grant — $336,883
- First Round $58,784
(Mar 2013)
- Investors Count 10
All 6 funding rounds of GenePath Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $336,883 | Grant | – | – | |
| Jun 2020 | Seed | – | Saama Capital | – | |
| May 2017 | $417,152 | Seed | – | – | |
| Feb 2016 | $294,400 | Seed | $3.49M | Snow Leopard Ventures | – |
| Aug 2014 | $1.08M | Seed | $3.48M | Snow Leopard Ventures | – |
| Mar 2013 | $58,784 | Angel Round | $••••• | Paresh Kale |
| Date | Valuation | Stage |
|---|---|---|
| Feb 2016 | $3.49M | •••••••• |
| Aug 2014 | $3.48M | •••••••• |
Last known valuation $3.49M (Feb 2016). 10 investors in total: 4 institutional and 6 angel.
Investors in GenePath Diagnostics
GenePath Diagnostics has secured backing from 10 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Saama Capital, Snow Leopard Global and Snow Leopard Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments and partnerships in diverse sectors. | 2012 | saama.vc | Bengaluru, India | |
Investment management for public and private equity between India and the USA. | 2016 | snowleopardglobal.com | Pune, India | |
Early-stage venture capital firm investing in India | 2012 | slventures.in | Pune, India | |
Science and technology between India and US are promoted. | 2000 | iusstf.org | Delhi, India | |
PM Prashant Mudgal | unknown_d6a7882371d54a5e8 | |||
SK Siddharth Karnik | unknown_dec47caa1cfe4090b | |||
AJ Ashwini Joglekar | unknown_ba3a3139a4294bdaa | |||
KI Khushru Irani | unknown_b44b9ad6bb4242419 | |||
AM Arbind Maheswari | unknown_6f8f2e1f8f024cd59 | |||
PK Paresh Kale | unknown_24f58c0449784dd08 |
Investor details for GenePath Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Genepath Diagnostics India Private Limited (GenePath Diagnostics)
Genepath Diagnostics India Private Limited is the primary company behind GenePath Diagnostics. The boards of the 2 registered companies of GenePath Diagnostics currently have 2 directors; the longest-serving is Nikhil Dileep Phadke, appointed in 2008. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nikhil Dileep Phadke DIN 01948010 | Director | 04 Mar 2008 | 18 yrs 7 mo | Causeway Healthcare Private Limited, Genepath Diagnostics India Private Limited |
| Christopher Leigh Kolenaty DIN 06477674 | Director | 20 Aug 2014 | 12 yrs 2 mo | Causeway Healthcare Private Limited, Genepath Diagnostics India Private Limited |
People of GenePath Diagnostics
7 people are tracked at GenePath Diagnostics (4 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
| Co-Founder & CEO | Leadership | |
| Co-Founder | Leadership | |
Vinayak Pai | Chief Financial Officer | Leadership |
Ajay Mundkur | Chief Operating Officer | Leadership |
Sawita Marathe | Manager, Operations | Team |
Nikita Somani | Trinee | Team |
Pradnya Shinde | Sr. Accountant (retainership Of GDSJ & Associates, Chartered Accountants) | Team |
Complete people profiles for GenePath Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of GenePath Diagnostics
Figures of Genepath Diagnostics India Private Limited, the primary company behind GenePath Diagnostics, for FY 2025. Revenue was ₹6.93 Cr (-25% year on year). Net loss was -₹4.91 Cr (-71% margin). EBITDA was -₹3.05 Cr (-44% margin). Revenue has grown at a compounded annual rate of -31% over three years and +8% over five years.
- ₹6.93 CrRevenue · FY 2025 · -25% YoY
- -₹4.91 CrNet loss · -71% margin
- -₹3.05 CrEBITDA · -44% margin
- ₹10,000Paid-up capital
- 52Employees (provident fund records)
- -31%Revenue CAGR, 3 years
- +8%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Genepath Diagnostics India Private Limited are on its company page.
Detailed financial statements for GenePath Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GenePath Diagnostics
4 dated milestones of GenePath Diagnostics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded GenePath Diagnostics is founded.
- Funding First funding round of $59K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Grant, of $337K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genepath Diagnostics
Complete news archive for GenePath Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenePath Diagnostics
GenePath Diagnostics was founded in 2008 and raised its 1st funding round 5 years after it was founded.
GenePath Diagnostics is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Nickhil Jakatdar is the CEO of GenePath Diagnostics, as recorded in our data. They have also founded this company.
GenePath Diagnostics is a funded company, having raised a total of $1.85M across 6 funding rounds to date. The company's 1st funding round was a Angel Round of $58.78K, raised on Mar 2013.
The primary company behind GenePath Diagnostics, Genepath Diagnostics India Private Limited, reported revenue of ₹6.93 Cr for FY 2025, down 25% year on year.
GenePath Diagnostics was founded in 2008 in Pune, India, as a provider of diagnostic solutions targeting infectious diseases, cancers, and genetic disorders. DNA and RNA-based tests are included in the portfolio, covering oncology, endocrinology, transplantation typing, hematology, pharmacogenetics, and pre-natal genetic testing. Detection services for HPV and COVID-19 infections are also handled, with operations focused on the biotechnology and healthcare sectors.
GenePath Diagnostics offers Custom Reagents, STI Kits, UTI Assays, and Respiratory Tests.
GenePath Diagnostics has 10 investors. Key investors include Saama Capital, Snow Leopard Global, Snow Leopard Ventures, Indo-U.S. Science and Technology Forum, and Prashant Mudgal.
The valuation of GenePath Diagnostics is $3.49M as of Feb 2016.
GenePath Diagnostics is associated with 2 legal entities: Genepath Diagnostics India Private Limited, Causeway Healthcare Private Limited.
The legal entities of GenePath Diagnostics currently have 2 directors, including Nikhil Dileep Phadke, Christopher Leigh Kolenaty.